Ocular Therapeutix Inc (NASDAQ: OCUL) is 125.56% higher on its value in year-to-date trading and has touched a low of $2.14 and a high of $11.77 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The OCUL stock was last observed hovering at around $9.75 in the last trading session, with the day’s gains setting it 0.31%.
Currently trading at $10.06, the stock is 1.38% and 1.22% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 3.18% at the moment leaves the stock 23.03% off its SMA200. OCUL registered 339.30% gain for a year compared to 6-month gain of 73.45%. The firm has a 50-day simple moving average (SMA 50) of $9.9392 and a 200-day simple moving average (SMA200) of $8.1768.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -10.97% loss in the last 1 month and extending the period to 3 months gives it a 17.52%, and is 14.58% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.38% over the week and 6.08% over the month.
Ocular Therapeutix Inc (OCUL) has around 267 employees, a market worth around $1.63B and $61.44M in sales. Profit margin for the company is -283.74%. Distance from 52-week low is 369.00% and -14.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-40.98%).
The EPS is expected to shrink by -15.62% this year
224.0 institutions hold shares in Ocular Therapeutix Inc (OCUL), with institutional investors hold 92.05% of the company’s shares. The shares outstanding are 157.22M, and float is at 135.43M with Short Float at 7.96%. Institutions hold 91.08% of the Float.
The top institutional shareholder in the company is SUMMER ROAD LLC with over 14.89 million shares valued at $101.82 million. The investor’s holdings represent 11.2751 of the OCUL Shares outstanding. As of 2024-06-30, the second largest holder is VR ADVISER, LLC with 12.76 million shares valued at $87.3 million to account for 9.6669 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 12.72 million shares representing 9.6359 and valued at over $87.01 million, while BLACKROCK INC. holds 8.7261 of the shares totaling 11.52 million with a market value of $78.8 million.
Ocular Therapeutix Inc (OCUL) Insider Activity
The most recent transaction is an insider sale by Heier Jeffrey S., the company’s Chief Scientific Officer. SEC filings show that Heier Jeffrey S. sold 2,948 shares of the company’s common stock on Nov 25 ’24 at a price of $9.01 per share for a total of $26561.0. Following the sale, the insider now owns 0.27 million shares.
Ocular Therapeutix Inc disclosed in a document filed with the SEC on Nov 25 ’24 that Kaiser Peter (Chief Development Officer) sold a total of 2,897 shares of the company’s common stock. The trade occurred on Nov 25 ’24 and was made at $9.01 per share for $26102.0. Following the transaction, the insider now directly holds 0.21 million shares of the OCUL stock.
Still, SEC filings show that on Nov 25 ’24, Nayak Sanjay (Chief Strategy Officer) disposed off 1,814 shares at an average price of $9.00 for $16326.0. The insider now directly holds 174,380 shares of Ocular Therapeutix Inc (OCUL).
